- The scientific leader of the project, Melnikov A.A., has been working in the field of molecular biology for over 42 years; and has written over 50 scientific articles. He has made the following scientific discoveries: he was the first to discover and study phagemids, a term still used in biology; he was the first to prove that the reverse transcriptase is coded by the LINE-elements of the human genome; he invented a new technology to analyze the methylation of the whole human genome.
- 10 years of work experience in the USA in oncological centers: working with sequencing DNA of blood plasma, while elaborating new methods of cancer diagnostics on the basis of DNA methylation analysis.
- A completely new technology of DNA amplification and hybridization to select informative genes from the whole human genome.
- In 2013 together with his son and a team of venture investors in Moscow he created the LLC “Biomarker-RU”, which allowed them to launch the companyʼs research diagnostic laboratory.
- In the beginning the laboratory functioned in cooperation with NN Blokhin Russian Cancer Research Center and Institute of Pathology and Pathophysiology RAMS. Now cooperation with Moscow City Oncological Hospital #62 and Sechenov First Moscow State University is being negotiated.
- ARNA-1 is the first cancer-specific marker developed by this project. It serves to determine whether a person has or doesn’t have an oncology disease, without localizing the tumor. Since this technology requires significant investments into extensive clinical research and much time for the method validation, it was decided to create a line of specific products based on ARNA-1.
- ARNA-BC is the second cancer-specific marker, and the first specific ARNA test, developed for breast cancer diagnostics.
ARNA Genomics today
We are ARNA Genomics. We are an innovative bio technological company, launched by a team of like – minded scientists and businessmen and grown from the scientific and research laboratory into full scale venture. We develop revolutionary early detection methods for select cancers in order to launch a line of diagnostic tests for early cancer detection on the global markets .
Our mission : to increase the life expectancy and significantly red uce human mortality . We relentlessly pursue this goal through cutting edge screening methods, diagnos is correction, treatment monitoring , and increasing patient adherence.
Our Innovation: ARNA Genomics has discovered a technology enabling highly specific t ests development for different cancers. Besides, the company has also developed a unique concept of blockchain – based ecosystem – grade platform intended for use as an instrument to support R&D and implementation of biotechnologies worldwide.
Our Pledge : ARNA Genomics have completed R&D for its first product – ARNA Breast Cancer test. The test for c olon cancer test is currently i n an advanced R&D stage. We devote all our resources to complete develop ment of ARNA Panacea – a blockchain platform, that will hope will change the world by making launch of new biotech and treatment solutions against cancer s much easier , cheaper and faster.
More than 10 years ago started the project with mission to save lives from cancer. Economist and manager by education, entrepreneur by experience and spirit. Made several successful startups as founder and co-founder in advertising and production business, international logistics, IT solutions for large-scale projects, was CEO of international telecom operator. ARNA – is the meaning of Egor’s life.
Master of physics (diploma with honors), have 14 articles and inventions. Successfully worked in large international companies (Delloite, etc.), as well as in private equity companies. He has extensive experience as executive manager in various major private and public companies in IT, telecom, oil&gas.
Having more than 40 years of experience in molecular biology and genetics, he is the author and co-author of more than 50 scientific articles and number of patents. For 15 years he worked in the USA in oncological centers, before that – in Canada, Hungary in various scientific companies, and Russia – a branch of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and the Institute of Biochemistry and Physiology of Microorganisms of the Russian Academy of Sciences. He graduated from the biological faculty of the Lomonosov Moscow State University.
Development Manager for Scientific and Educational Programs (F. Paulsen Assisted Reproductive Technologies Center, Russian Ministry of Health). Former: medical advisor (MC Femina, Vitrolife), clinical embryologist (MD Medical Group), Jr. scientist (Wageningen University, The Netherlands)
Branch of the Institute of Bioorganic Chemistry Acad. M.M. Shemyakin and A. Ovchinnikov Institute of Sciences, Pushchino. Specialization — molecular biology, biotechnology, genetic engineering. Area of scientific expertise: regulation of gene expression, transcription, translation, molecular mechanisms of bacterial phage lysis.
Software architect and developer. Has a big experience working with start-ups in the areas of e-commerce, PR & Marketing, finance, transportation, ERP development. Mainly focused on building SaaS, APIs & complex business processes automation. Had been working in international companies in Russia, Ireland, and Germany.
Founder, CEO and Principal engineer in blockchain integrator Dicoiner (www.dicoiner.com) Founder and CEO in mobile development studio Zero Cool Team. 10 years experience in enterprise fintech software design and development. Last two yeast making research and implementation of blockchain systems. Graduate of IIDF-2015(Internet Initiatives Development Fund) in the team of Teslawatch startup.
15 scientific publications in the field of natural language processing
Entrepreneur and co-owner of several companies in the oilfield service, medicine and biotech. He graduated from the Faculty of Computational Mathematics and Cybernetics of the Moscow State University Lomonosov, EMBA Higher School of Economics, studied at the Skolkovo Management School, INSEAD and graduate school of MGIMO. He has extensive executive experience in oil&gas public and private companies.
has a master’s degree in physics. During his professional experience, he worked in various business areas, mainly focusing on the active development of the contractual base of enterprises. He has experience in working in a Western consulting company, a resort development company, a Swiss investment fund and a Russian exploration company.
Ron Ribitzky, MD
Dr. Ribitzky brings to ARNA 30 years of cross-functional C-level experience in the converging Healthcare IT, Life-Sciences Informatics, and Precision Medicine. Prior to co-founding SPH Analytics, Dr. Ribitzky was Senior Healthcare Strategist at Intel, CIO at UMass Medical Center, VP Emerging Technologies at Eclipsys etc. He held academic appointments at Harvard Medical School, University of Massachusetts Medical School, Emory School of Public Health, Weitzmann Institute of Science (Israel), Kigali Institute of Science & Technology, and Kigali Health Institute (Rwanda).
Linda S. Pellicore
Linda S. Pellicore graduated from Thomas Jefferson Medical College of Graduate Studies, Philadelphia, PA, with Ph.D.s in both Pharmacology and Toxicology, in 1987. She has 28 years expertise in New Drug Applications, Biologics, 510Ks, Food Additives and Dietary Supplements with the U.S. Food and Drug Administration, serving as the agency’s Senior Pharmacologist. She is a National Research Council Fellow, and is a member of numerous professional scientific societies.
Wesley Hymer, Ph.D
Dr. Hymer is an Emeritus Professor of Biochemistry at Penn State and winner of Penn State’s Faculty Scholar Medal for Life and Medical Sciences. He has countless academic papers, grants and including several patents that were developed when he was Director of Penn State’s Center for Cell Research, and one patent related to medical devices enabling targeted chemotherapy for cancers treatments. He collaborated with NASA on biotechnology and biomedical experiments in microgravity and developed unique electrophoresis experiments executed on board the U.S. Space Shuttle and microsatellites.
Dmitry Kulish is an independent expert in the fields of strategic, organizational and technological development of pharmaceutical products. Dmitry holds a PhD in Biology, has been a postdoc at Harvard Medical School, earned MBA from the Wharton Business School, the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Moscow State Institute of Molecular Biology Lomonosov Moscow State University.
Over 20 years of successful general management experience with a particular focus on business development and operational excellence. Сonstant over 5 years trend in business development and financial results improvement for large European integrated company with over 8 bln. USD in turnover and presence in over 15 countries. Has implemented several very successful business alliances strategies where the managed companies/clients have benefited from new distribution channels/partners reach.
Ph.D DR. Soenke Bartling
Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
is a Doctor of Medical Sciences, a laureate of the Russian Government Prize in Science, a holder of post-doctoral degree in medicine of the Technical University of Munich, the Director of the Center for Personalized Oncology Sechenov OncoTarget, established as part of the Institute of Personalized Medicine in 2017
Ilya N. Chistyakov
MD., PhD, founder and CEO of the Preclinical Study Centre LLC, managing company of “Pharma Valley” biotechnological cluster – the only GLP OECD in Russia, an independent hybrid CRO specialized on conducting a full cycle of pharmacological development, manufacturing, preclinical and clinical studies of biotechnological, biosimilar and generic medicines.
has more than 20 years of experience in biotech investments and strategic consulting. Partner of venture fund “Maxwell Biotech” (Moscow), director of consulting company Candesic (London). Edward is an acting head of Investment Service of Skolkovo fund, vice-president of Investment Bank “Trust” and consultant of New Jersey office of McKinsey company. His career has started in Bill and Melinda Gates Foundation Fund. MBA from Harvard Business School, MD with PhD.
Dr. Alex Kоsik is a successful serial technology entrepreneur. His focus is in Life Sciences, Medical Devices, FDA Compliance, Evidence-Based Medicine, Venture Capital and M&A. Alex is a recognized technology due diligence expert and senior analyst to several VC’s, angels, Gerson Lehrman Group and institutional investors. He co-founded multiple businesses himself, met Bill Gates, sold his “G1 Gravitonus workstations” to Forbes-100, and ranked 3rd by Becker’s Spine Review of “10 spine orthopedic surgeon tech entrepreneurs to know”
worked and lived in China since 1991. He has more than 20 years of experience in international management in China and Hong Kong. He held the positions of Chairman of the Board of Directors in various companies in China involved in international trade, investment and production. Since 2017, he was the General Manager of Sanju Environmental Protection (Hong Kong) Limited, coordinating the international projects of the controlling shareholder.